How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening

Por Wever, Elisabeth M., Draisma, Gerrit, Heijnsdijk, Eveline A.M., de Koning, Harry J.
Publicado no Med Decis Making (2011)

The impact of PLCO control arm contamination on perceived PSA screening efficacy

Por Gulati, Roman, Tsodikov, Alex, Wever, Elisabeth M, Mariotto, Angela B, Heijnsdijk, Eveline AM, Katcher, Jeffrey, de Koning, Harry J, Etzioni, Ruth
Publicado em 2012

Race-Specific Impact of Natural History, Mammography Screening and Adjuvant Treatment on Breast Cancer Mortality Rates in the US

Por van Ravesteyn, Nicolien T., Schechter, Clyde B., Near, Aimee M., Heijnsdijk, Eveline A.M., Stoto, Michael A., Draisma, Gerrit, de Koning, Harry J., Mandelblatt, Jeanne S.
Publicado em 2010

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Por Vickers, Andrew J, Sjoberg, Daniel D, Ulmert, David, Vertosick, Emily, Roobol, Monique J, Thompson, Ian, Heijnsdijk, Eveline AM, De Koning, Harry, Atoria-Swartz, Coral, Scardino, Peter T, Lilja, Hans
Publicado em 2014

The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines

Por Etzioni, Ruth, Gulati, Roman, Tsodikov, Alex, Wever, Elisabeth M, Penson, David F, Heijnsdijk, Eveline AM, Katcher, Jeffrey, Draisma, Gerrit, Feuer, Eric J, de Koning, Harry J, Mariotto, Angela B
Publicado em 2012

Transition From Film to Digital Mammography: Impact for Breast Cancer Screening Through the National Breast and Cervical Cancer Early Detection Program

Por van Ravesteyn, Nicolien T., van Lier, Lisanne, Schechter, Clyde B., Ekwueme, Donatus U., Royalty, Janet, Miller, Jacqueline W., Near, Aimee M., Cronin, Kathleen A., Heijnsdijk, Eveline A.M., Mandelblatt, Jeanne S., de Koning, Harry J.
Publicado no Am J Prev Med (2015)

Estimating the Harms and Benefits of Prostate Cancer Screening As Used in Common Practice Versus Recommended Good Practice: A Microsimulation Screening Analysis

Por Carlsson, Sigrid V., de Carvalho, Tiago M., Roobol, Monique J., Hugosson, Jonas, Auvinen, Anssi, Kwiatkowski, Maciej, Villers, Arnauld, Zappa, Marco, Nelen, Vera, Páez, Alvaro, Eastham, James, Lilja, Hans, de Koning, Harry J., Vickers, Andrew J., Heijnsdijk, Eveline A.M.
Publicado no Cancer (2016)

What level of risk tips the balance of benefits and harms to favor screening mammography starting at age 40?

Por van Ravesteyn, Nicolien T., Miglioretti, Diana L., Stout, Natasha K., Lee, Sandra J., Schechter, Clyde B., Buist, Diana S.M., Huang, Hui, Heijnsdijk, Eveline A.M., Trentham-Dietz, Amy, Alagoz, Oguzhan, Near, Aimee M., Kerlikowske, Karla, Nelson, Heidi D., Mandelblatt, Jeanne S., de Koning, Harry J.
Publicado em 2012

Personalizing Age of Cancer Screening Cessation Based on Comorbidity: Model estimates of harms and benefits

Por Lansdorp-Vogelaar, Iris, Gulati, Roman, Mariotto, Angela B, Schechter, Clyde B, de Carvalho, Tiago M, Knudsen, Amy B, van Ravesteyn, Nicolien T, Heijnsdijk, Eveline AM, Pabiniak, Chester, van Ballegooijen, Marjolein, Rutter, Carolyn M, Kuntz, Karen M, Feuer, Eric J, Etzioni, Ruth, de Koning, Harry J, Zauber, Ann G, Mandelblatt, Jeanne S
Publicado em 2014